key: cord-0708888-r61angi6 authors: Lemos-Perez, G.; Chavez-Valdes, S.; Gonzalez-Formental, H.; Freyre-Corrales, G.; Vazquez-Arteaga, A.; Alvarez-Acevedo, B.; Avila-Diaz, L.; Martinez-Rosales, R. U.; Chacon-Quintero, Y.; Coizeau-Rodriguez, E.; Palenzuela-Diaz, A.; Noa-Romero, E.; Guillen, G. title: Elevated antibody titers in Abdala vaccinees evaluated by Elecsys(R) anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assays. date: 2021-10-19 journal: nan DOI: 10.1101/2021.10.18.21265169 sha: f65c815e9f5cf73d9d2932036f03e2b9a5857074 doc_id: 708888 cord_uid: r61angi6 SARS-CoV-2, a recently emerged coronavirus, is causing high morbidity and mortality worldwide since December 2019, posing an enormous health, social and economic problem. Obtaining effective treatments that can diminish deaths and sequelae and vaccines to slow or prevent viral transmission, and reduce disease severity and/or death are of utmost importance. Abdala is a Cuban vaccine based on the recombinant RBD subunit of the spike protein expressed in Pichia pastoris yeast. It demonstrated high efficacy (92.28 %) in phase III clinical trials for reducing transmission, and more than 90% effectiveness in reducing disease severity and mortality. Antibody titers were evaluated in 42 Abdala vaccinees using the Elecsys(R) Anti-SARS-CoV-2 S test. Fifteen days after immunization, sera from vaccinees showed high antibody titers (median of 1595 U/mL). The results obtained in this study also demonstrate correlation between the Cuban test UMELISA SARS-CoV-2 ANTI RBD used during the clinical trials and Elecsys(R) test results. COVID-19 is a severe disease produced by a new coronavirus (SARS-CoV-2), whose first victims were reported in Wuhan, China, in late 2019. This disease rapidly spread to other provinces in China and to the rest of the world [1] . By the end of January 2020, The World Health Organization (WHO) declared this disease a global health emergency [2] , and it was recognized as a pandemic in March 2020 [3] . On March 23, confirmed SARS-CoV-2 cases exceeded 3,000 globally; the disease was present in 185 territories in six continents. The death total was 14,502. Together with the well-known containment measures for respiratory infection control, testing of suspected cases and contacts (with or without symptoms) by rRT-PCR was highly recommended [4] . On March 27, 2020, the USA became the country with the most confirmed cases, surpassing China. A few days later (on April 3), the number of confirmed cases globally exceeded one million and global deaths surpassed 56,000 [5] . In Cuba, the first COVID-19 case was confirmed on March 11 [6] . The rapidly growing infection rate of SARS-CoV-2 worldwide that poses enormous health, social and economic problems, triggered a race for developing diagnostics, therapeutic agents and vaccines, which might ultimately slow or prevent viral transmission. The entire genome structure of SARS-CoV-2 (COVID-19 etiologic agent) was made available since early January 2020 [7] . It is almost identical to SARS-CoV except for some additional protein genes and its host receptor, the ACE-2 (angiotensinconverting enzyme 2) protein that allows entry into the cell. Among the structural proteins of SARS-CoV-2, the spike (S) and nucleocapsid are the main immunogens used in diagnosis. The S protein contains two subunits, S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which is responsible for recognition and binding to the cell surface receptor, making it the main target for vaccine development. The S2 subunit contains other basic elements necessary for membrane fusion [8, 9] . Cuba worked on five vaccine candidates [11] . The Cuban Center for Genetic Engineering and Biotechnology (CIGB) obtained Abdala®, a Cuban vaccine also named CIGB-66, based on the recombinant RBD subunit of the spike protein produced in Pichia pastoris yeast [12] . Its first clinical trial, a Phase I/II trial, began on December 7, 2020 [13] and the Phase III trial was started on March 22, 2021 [13] with a 92.28% efficacy result [15, 16] . At the same time, since the city of Havana became the epicenter of community transmission in Cuba, a vaccine intervention with Abdala was carried out in this city from March 29 to September 30, 2021 [17] . The vaccine was approved for emergency use on July 9 [18, 19] . Recent reports have shown that the Abdala vaccine was more than 90% effective against severity and death, despite the prevalence of the Delta variant of SARS-CoV-2 [20] . There are currently two ongoing clinical trials, one in pediatric ages 3 to 18 years and another in convalescents, in whom the immune response is boosted with a single dose of the Abdala or the nasal vaccine candidate Mambisa (CIGB-669, Cuba), one of the nine on trial using this route of administration [21] . The latter completed a successful Phase I trial in healthy and convalescent subjects [22, 23] . High antibody titers, primarily IgG, correlate with good virus neutralizing levels and thus protective immunity [24, 25] . The objective of this study was to evaluate serum samples from Abdala vaccinees using the Elecsys® Anti-SARS-CoV-2 S system (Roche Diagnostics, Switzerland) and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 19, 2021. ; correlating the results with those previously obtained with the Cuban test (UMELISA SARS-CoV-2 ANTI RBD). The Cuban Abdala vaccine (CIGB-66) developed by the CIGB (Center for Genetic Engineering and Biotechnology, Cuba) was administered as immunogen [12, 19, 20] . The study was carried out using sera collected from 42 individuals immunized with the Abdala vaccine candidate. In total 126 sera were used: prior to immunization (Pre), and fifteen days post both the second and the third (last) immunizations (Post). Collected sera were stored at -20 o C until evaluation. Subjects gave their consent after being informed that the immediate use of the samples was to determine post vaccination antibody titers and there were possibilities of their use in other related research. Confidentiality of the donors' personal data was ensured. The study was approved by CIGB Ethics Committee in Havana, Cuba. Elecsys® Anti-SARS-CoV-2 S assay SARS-CoV-2 antibodies against the Spike RBD viral protein were determined using the quantitative Elecsys® Anti-SARS-CoV-2 S test on the Cobas e411 Analyzer (Roche Diagnostics). The test is a double-antigen sandwich electro-chemiluminescence immunoassay, which uses streptavidin-coated microparticles to separate bound from unbound substances prior to applying voltage to the electrode. This assay has a measuring range of 0.40−250 U/mL (up to 2500 U/mL with on-board 1:10 dilution), with a concentration ≥0.80 U/mL considered positive. The manufacturer specific U/mL of the Elecsys® Anti-SARS-CoV-2 S assay can be considered equivalent to the BAU/mL of the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin [26] . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 19, 2021. ; distilled water, the plates were blocked with 2% (w/v) nonfat dry milk powder in PBS for 1h at 37°C. During the coating incubation period, the samples and assay controls is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 19, 2021. ; https://doi.org/10.1101/2021.10.18.21265169 doi: medRxiv preprint detected at 540 nm. The highest serum dilution showing an OD value larger than the cut-off was considered the neutralization titer. The cut-off value is calculated as the average of the OD of the cell control wells divided by two. Viral neutralizing titers (VNT50) were calculated as the highest serum dilution at which 50 % of the cells remain intact according to neutral red incorporation in the control wells (no virus added). All statistical analyses were performed by GraphPad Prism v. 8.0. In line with common conventions of descriptive statistics, standard deviation (SD) was calculated for mean values and interquartile range (IQR) for median values, geometric mean titer (GMT) and 95% confidence intervals (CIs) were also estimated. We used Wilcoxon matchedpairs signed rank test to compare the pre and post-immunization titers of serum samples and Spearman non-parametric correlation coefficient (Spearman's rho, r) test to perform inferential analysis among tests results with the categories: none or very weak r < 0.3, weak 0.3 < r <0.5, moderate 0.5 < r < 0.7 and strong r > 0.7. Cohen's kappa () [9] was calculated to assess the agreement between the test assays with the categories of poor Antibody titers obtained with the Elecsys ® Anti-SARS-CoV-2 S test in Abdala vaccinees are shown in Figure 1 . Prior to immunization, only one sample showed detectable anti-RBD antibodies (≥ 0.80 U/mL) by the Roche test. Post-vaccinated sera showed a GMT of 1382 U/mL (95% CI: 850.7-2247), that represents a 3191.7-fold increase compared to the baseline value of 0.43 U/mL obtained before immunization. In Abdala vaccinated individuals, the seroconversion rate 15 days after the last dose was 100% by the Roche test. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 19, 2021 The degree of agreement between both tests was analyzed in 126 evaluated samples. Results are shown in Table 1 . The concordance value () obtained was 0.873 (95% CI, 0.781 to 0.964). Table 1 . Two-way contingency table for anti-RBD antibody detection using UMELISA SARS-CoV-2 ANTI RBD and Elecsys ® Anti-SARS-CoV-2 S (considered the gold standard test). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 19, 2021. ; During serological studies of the Cuban COVID-19 vaccine candidates, throughout the preclinical and clinical phases, the abovementioned Cuban commercial and in-house tests have been used. It is important to note that the proteins used for IgG quantification or the inhibition assays were obtained in mammalian cells, a heterologous expression system with respect to the one used for obtaining the vaccine antigen. Although the antibody quantification assays used in this study have different principles, and moreover, the Roche sandwich test detects total high affinity antibodies and UMELISA detects IgG type antibodies, both had an almost exact agreement (= 0.873) and a strong positive correlation (r=9589). sVNT and VNT50 assays also showed a positive and strong correlation with the Elecsys® Anti-SARS-CoV-2 S test (rho value of 0.911 and 0.8773 respectively). The different tests used (the in-house sVNT and the UMELISA SARS-CoV-2 ANTI RBD assays (Immunoassay Center, Cuba) showed strong positive correlation with the Elecsys® Anti-SARS-CoV-2 S test (Roche, USA) for antibody detection. Since the last is considered the WHO reference standard, the conclusion is that both the in-house and the Cuban UMELISA system are equally accurate for detecting anti-SARS-CoV-2 antibodies. The VNT using live virus also strongly correlates with them, but must be carried out under more stringent biosafety conditions. Indirectly, the results also show the high immune stimulating capability of the Abdala vaccine, whose vaccinees reach antibody titers by the Elecsys® Anti-SARS-CoV-2 S test similar to those of other approved vaccines like Pfizer-BioNTech when evaluated with the same commercial test. Statement regarding cluster of pneumonia cases in Wuhan COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum Available at COVID-19) outbreak -WHO announces COVID-19 outbreak a pandemic Available WHO. Coronavirus disease 2019 (COVID-19) Situation report WHO Coronavirus disease 2019 (COVID-19) Situation report 75 Protocolo vs COVID-19 Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome (NCBI Reference Sequence: NC_045512.2) Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines Cuba's five COVID-19 vaccines: the full story on Soberana 01/02/Plus, Abdala, and Mambisa. London School of Economics (LSE) Latin America and Caribbean blog The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigen Registro Público Cubano de Ensayos Clínicos (RPCEC) Registro Público Cubano de Ensayos Clínicos (RPCEC) Cuban COVID vaccine Abdala 92 percent 'effective', maker says Eric Caraballosa How was the efficacy of the Cuban COVID-19 vaccine candidates Cuba approves emergency use of home-grown COVID vaccine, Latin America's first Aprueba el CECMED el autorizo de uso de emergencia del candidato vacunal cubano ABDALA Available at: prensalatina.cu/index.php?o=rn&id=479325&SEO=vacuna-abdala-con-alta-efectividad-en-lacapital-de-cuba 21. WHO. Overview WHO COVID vaccine tracker and Landscape Cuban Public Registry of Clinical Assays. CIGB-Mambisa SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics (Basel) Immunoassay intended for qualitative detection of antibodies to SARS-CoV-2 in human serum and plasma Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples WHO. Evidence Assessment: ChAdOx1-S [recombinant] vaccine (AZD1222) vaccine against COVID-19 developed by Oxford University and Astra Zeneca Sputnik V COVID-19 vaccine candidate appears safe and effective World Health Organization. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine Bloomberg vaccine tracker. More Than 6.56 Billion ShotsGiven: Covid-19 Tracker Available at Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins Geneva Centre for Emerging Viral Diseases. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study The authors would like to express their gratitude to Dr. Loida Torres from the International Health Center "La Pradera" for enabling the use of its facilities and the equipment necessary for the evaluation of the samples.Research reported here was supported with funds from the BioCubaFarma Enterprise and the Center for Genetic Engineering and Biotechnology in Cuba.